Future Oncology
| 短名 | Future. Oncol. |
| Journal Impact | 2.88 |
| 国际分区 | ONCOLOGY(Q2) |
| 期刊索引 | SCI Q3中科院 4 区 |
| ISSN | 1479-6694, 1744-8301 |
| h-index | 90 |
| 国内分区 | 医学(4区)医学肿瘤学(4区) |
未来肿瘤学 (ISSN 1479-6694) 为癌症治疗的新时代提供了一个论坛。该杂志重点关注最重要的进展，并强调它们在临床环境中的相关性。此外，FUTURE ONCOLOGY 以简洁、一目了然的文章格式提供重要信息——这对于向时间越来越紧迫的社区提供信息至关重要。该杂志对科学和临床问题以及经济和在这个癌症治疗的新时代，我们面临的政策问题。该杂志包括文献意识，例如放射治疗和免疫治疗的最新发展、简明的评论和分析以及完整的评论文章，所有这些文章都提供了关键发现，并转化为临床环境。
期刊主页投稿网址| 涉及主题 | 医学内科学生物遗传学癌症肿瘤科病理外科化学生物化学癌症研究免疫学化疗基因放射科生物信息学 |
| 出版信息 | 出版商: Taylor and Francis Ltd.，出版周期: Monthly，期刊类型: journal |
| 基本数据 | 创刊年份: 2005，原创研究文献占比: 82.55%，自引率:3.30%， Gold OA占比: 44.63% |
| 平均审稿周期 | 网友分享经验：偏慢,4-8周 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer
2024-9-17
T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas
2024-9-13
The role of multiparametric MRI in predicting lymphovascular invasion in breast cancer patients
2024-9-13
Neo-adjuvant radiation and intratumoral immunotherapy followed by surgery- <i>NARIS</i> trial for extremity soft tissue sarcoma
2024-9-13
Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals
2024-9-13
The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapy
2024-9-12
Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases
2024-9-12
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
2024-9-12
Breaking barriers: the latest insights into KRAS G12C inhibitors
2024-9-12
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review
2024-9-11
Patterns and outcomes in HR+/HER2- advanced/metastatic breast cancer patients in Brazil receiving palbociclib
2024-9-5
Cancer immunotherapy of Wilms tumor: a narrative review
2024-9-5
Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile
2024-9-4
Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients
2024-9-4
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
2024-9-4
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with <i>KIT</i> exon 11 + 17/18 mutations
2024-9-4
Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors
2024-9-4
Carotid ultrasound to identify head and neck cancer survivors with high cardiovascular risk after radiation therapy: rationale and design of a prospective, cross-sectional pilot study
2024-9-4
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study
2024-9-3
Leveraging multi-cancer blood tests to improve diagnostic efficiency for patients with nonspecific signs and symptoms
2024-8-28
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies
2024-8-20
Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs
2024-8-19
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
2024-8-19
Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA
2024-8-19
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe
2024-8-14
A perioperative study of Safusidenib in patients with <i>IDH1</i> -mutated glioma
2024-8-14
Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review
2024-8-12
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study
2024-8-12
Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis
2024-8-12
Knowledge and attitude toward proton radiotherapy among oncology patients: a multi-center, cross-sectional study
2024-8-12
Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe
2024-8-9
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
2024-8-8
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain
2024-8-8
Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
2024-8-7
Risk factor and prediction model development for severe radiation-induced oral mucositis in head and neck tumors
2024-8-6
Expression of integrin α <sub>v</sub> β <sub>3</sub> in medullary thyroid carcinoma
2024-8-5
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
2024-8-5
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
2024-7-31
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review
2024-7-29
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
2024-7-29
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial
2024-7-29
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
2024-7-29
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
2024-7-29
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
2024-7-29
Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer
2024-7-29
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial
2024-7-29
Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population
2024-7-26
Prevalence and predictors for cisplatin-induced toxicities in Zimbabwean women with cervical cancer
2024-7-26
The TALAPRO-3 study design: a plain language summary
2024-7-24
Gastric cancer in pregnancy: a review
2024-7-23
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远